What does MediWound do and what are its main business segments?

What guidance did MediWound's management provide for the next earnings period?

What is the market's earnings forecast for MediWound next quarter?

What is the revenue and EPS growth rate for MediWound year over year?

What were the key takeaways from MediWound’s earnings call?

Did MediWound beat or miss consensus estimates last quarter?

What factors drove the changes in MediWound's revenue and profit?

What is MediWound's latest dividend and current dividend yield?

- **Clinical Momentum**: EscharEx Phase III VLU trial on track for 2026 completion; DFU and pressure ulcer trials expanding addressable market. 
- **Manufacturing Scale-Up**: NexoBrid capacity increased sixfold, positioning for 2026 commercial launch. 
- **Financial Resilience**: $53.6M cash balance supports multiyear growth despite 2025 revenue decline to $17M. 
- **Strategic Partnerships**: B. Braun collaboration enhances EscharEx clinical validation; 7+ wound care partners support trial execution. 
- **Revenue Outlook**: 2026 guidance ($24-26M) reflects BARDA/DOD funding and NexoBrid ramp-up, with 2028 target of $50-55M.

**【CEO Opening Remarks】**
- 2025 was a pivotal year with Phase III VALUE trial advancing and expanded NexoBrid manufacturing facility operational. 
- EscharEx Phase III trial for venous leg ulcers (VLUs) targets 216 patients by end-2026, with interim analysis at 65% enrollment. 
- EscharEx expansion into diabetic foot ulcers (DFUs) and pressure ulcers via Phase II trials, with B. Braun collaboration for DFU study. 
- NexoBrid production capacity increased sixfold, awaiting regulatory approvals for commercial output in 2026. 
- Reaffirmed 2026-2028 revenue guidance ($24-26M/2026, $32-35M/2027, $50-55M/2028), contingent on BARDA/DOD support. 

**【CFO Financial Commentary】**
- Q4 2025 revenue: $1.9M (vs. $5.8M in Q4 2024), driven by U.S. government shutdown delays. 
- Full year 2025 revenue: $17M (vs. $20.2M in 2024), with R&D expenses up 67% to $14.3M. 
- Net loss for 2025: $23.9M ($2.10/share), improved from $30.2M ($3.03/share) in 2024 due to warrant revaluation. 
- Cash balance: $53.6M (vs. $43.6M in 2024), supported by $30M registered direct offering. 

**【Q&A Highlights】**
- **Manufacturing Expansion**: Expanded NexoBrid facility operational, awaiting 2026 regulatory approvals for commercial launch. 
- **EscharEx Pressure Ulcer Trial**: 50-patient Phase II study to begin H2 2026, with potential for 1/3 of peak sales. 
- **BARDA/DOD Support**: 2026 revenue guidance assumes BARDA stockpiling and DOD funding ($18.2M awarded to date). 
- **Supply Chain Resilience**: Sufficient EscharEx inventory for clinical trials despite geopolitical tensions. 
- **Revenue Timing**: BARDA-related revenue expected from Q2 2026, with H2 2026 revenue growth driven by manufacturing ramp-up.

MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript

- **EscharEx Peak Sales Estimate**: Updated to $831M, driven by HEOR benefits and 50% premium pricing strategy.
- **NexoBrid Growth**: 38% YoY revenue growth, 6x manufacturing capacity expansion on track for 2025. BARDA contract resumption expected post-shutdown.
- **Financial Resilience**: $60M cash position supports strategic initiatives, 9M gross margin 19.7%.

**【CEO Summary Section】**
- **EscharEx VLU Trial Progress**: Enrollment in the Phase III trial for venous leg ulcers (VLU) is on track with 216 patients across 40 U.S. and EU sites. The trial aims to assess complete debridement and wound closure, with a prespecified interim analysis at 65% enrollment. Medicare's reduced reimbursement for skin substitutes highlights EscharEx's potential in the enzymatic debridement market ($370M annually). Updated U.S. peak sales estimate is $831M, driven by HEOR benefits and a 50% premium over legacy product pricing.
- **NexoBrid Manufacturing Expansion**: New facility increases production capacity by 6x, with full operational readiness by year-end 2025. Vericel reports 38% YoY revenue growth, and NexoBrid is approved in 45 countries. BARDA contract progress paused due to U.S. government shutdown, but expected resumption post-shutdown.
- **Financial Strength**: $30M equity financing strengthens balance sheet, supporting strategic initiatives.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Revenue $5.4M (23% YoY), gross profit $0.9M (16.5% margin). R&D expenses $3.5M (+40% YoY) due to EscharEx trial. Operating loss $6.5M, net loss $2.7M. 9M 2025 cash position $60M, up from $44M at year-end 2024.
- **Key Metrics**: Adjusted EBITDA loss $5.4M (Q3) and $13.9M (9M). Gross margin improvement to 19.7% for 9M, driven by favorable revenue mix.

**【Q&A Highlights】**
- **EscharEx Pricing Strategy**: Conservative $831M peak sales estimate reflects 15-50% premium over legacy product. DFU trial expected H2 2026. CPT code progress and HEOR benefits key to adoption.
- **BARDA Contract Update**: Vericel awaits contract award post-shutdown. NexoBrid's temporary CPT code supports 60+ burn centers, with permanent code sought for 2027. Manufacturing expansion to meet global demand.

MediWound Ltd. (MDWD) Q3 2025 Earnings Call Transcript

- **EscharEx Clinical Momentum**: Phase III trial enrollment progressing; post-hoc analysis validates wound bed preparation as key to healing. Head-to-head trial vs. Santyl planned for H2 2025.
- **NexoBrid Growth**: U.S. revenue +52% YoY; manufacturing expansion on track for 2026 FDA/EMA approvals. $18.2M in non-dilutive funding for U.S. manufacturing and room-temperature formulation.
- **Financial Position**: Q2 revenue $5.7M (+43% QoQ); operating loss $5.7M due to R&D. $32.9M cash with $32M potential from warrants. 2025 revenue guidance of $24M achievable through development services.

**【CEO Opening Remarks】**
- **EscharEx Phase III Trial Progress**: Enrollment in the VALUE trial for venous leg ulcers (VLUs) is actively progressing across 40 U.S. and European sites. A post-hoc analysis of the Phase II trial confirmed that wound bed preparation is a key predictor of healing, with EscharEx achieving a 4x higher likelihood of wound closure. Collaborations with global wound care leaders (Essity, Convatec, Solventum) enhance trial credibility.
- **NexoBrid Growth**: U.S. revenue grew 52% YoY, driven by hospital adoption. Manufacturing scale-up is on track for completion by year-end, with potential FDA/EMA approvals in H1/H2 2026. BARDA awarded $3.6M for a room-temperature stable formulation, bringing total funding to $18.2M.
- **Strategic Milestones**: Targeting 65% patient completion in the VALUE trial for an interim analysis by mid-2026. Planning for a head-to-head trial vs. Santyl (collagenase) in H2 2025.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Revenue $5.7M (+43% QoQ, +12% YoY), driven by NexoBrid sales and favorable mix. Gross margin improved to 23.5% (vs. 8.8% YoY). Operating loss $5.7M (+27% YoY) due to R&D and share-based compensation. Net loss $13.3M (-$1.23/share), including $6.6M non-cash warrant revaluation.
- **H1 2025 Performance**: Revenue $9.7M (-3% YoY) due to declining BARDA R&D revenue. R&D expenses doubled to $6.4M (+100% YoY) for EscharEx trials. Cash balance $32.9M, with $32M potential from in-the-money warrants expiring in 2026.

**【Q&A Highlights】**
- **Trial Enrollment**: U.S. sites fully active; Europe lagging due to regulatory delays. 50% of 40 planned sites active globally. No significant competition from CTP trials.
- **Manufacturing Timeline**: New facility commissioning on track for Q4 2025. FDA/EMA approvals expected H1/H2 2026. Current NexoBrid inventory sold immediately, with 2025 revenue growth from development services.
- **BARDA & DoD Funding**: $18.2M for room-temperature NexoBrid; BARDA RFP includes stockpiling and trauma solutions. U.S. manufacturing site planning fully funded by BARDA.
- **Reimbursement Impact**: Medicare changes may favor EscharEx by requiring wound bed preparation before CTP application, aligning with its clinical evidence.

MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript

- **EscharEx Clinical Dominance**: Phase III trial on track with 216-patient recruitment; head-to-head vs. Collagenase to begin Q3. Peer-reviewed data show 58% debridement success vs. 14% placebo.
- **NexoBrid Growth Engine**: U.S. sales +207% YoY; new manufacturing to meet 2026 global demand. U.S. backup facility planning underway with BARDA support.
- **Government Interest Surge**: Multiple countries exploring stockpiling post-conflict; BARDA-backed U.S. manufacturing expansion to support emergency readiness.
- **Financial Stability**: $38.7M cash, 2025 guidance of $24M revenue. Non-cash warrant revaluation impacts quarterly results, but core operations on track.

**【CEO Summary Section】**
- **EscharEx Phase III Trial Progress**: Recruitment on track for 216 patients across 40 global sites (50% in the U.S.). Interim analysis at 65% enrollment planned for mid-2026. A head-to-head study vs. Collagenase (SANTYL/IRUXOL) to begin Q3 2025, targeting 45 patients.
- **NexoBrid Global Momentum**: Q1 2025 U.S. sales up 207% YoY; Japan and Europe demand exceeds capacity. New manufacturing facility in Israel set for 2025H2 regulatory approvals, with U.S. backup facility planning supported by BARDA.
- **Strategic Collaborations**: Nearly all major wound care companies (Solventum, Mölnlycke, Kerecis, MIMEDX) now part of clinical programs. Peer-reviewed data highlight EscharEx's superior debridement (58% vs. 14%) and faster wound closure (23 days vs. 128 days) vs. placebo.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: Total revenue $4M (down 20% YoY), driven by reduced BARDA services. Gross margin improved to 19% (vs. 12% YoY). R&D expenses $2.9M (up 93% YoY) due to EscharEx trial investment. Operating loss $5.2M (up 40% YoY). Net loss $0.7M ($0.07/share), narrower due to warrant revaluation gains.
- **Cash Position**: $38.7M as of Q1 2025, down $5.1M from Q4 2024. 2025 guidance: $24M total revenue, with $30-33M expected in 2026 post-manufacturing ramp.

**【Q&A Key Highlights】**
- **Manufacturing Timeline**: Israel facility operational by end-2025, FDA/EMA inspections Q2 2026. U.S. backup facility site selection to begin Q3 2025, supported by BARDA.
- **EscharEx Enrollment**: 50% U.S. sites, 30% Europe. Screened 1.5M U.S. patients; targeting 0.5 patients/site/month. No expectation of early completion.
- **Government Stockpiling**: Multiple countries (U.S., Europe) expressing interest post-Israel-Hamas conflict. Revenue impact TBD, but 2025 guidance excludes stockpiling.
- **Financial Volatility**: Warrant revaluation (total $34M expiring Nov 2026) drives non-cash income/expense. Q1 2025 financial income $0.7M due to share price decline.


MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

- **EscharEx Clinical Superiority**: Outperforms SANTYL in debridement speed (5-6 weeks vs. 6-8 weeks) and closure rates, with $725M peak sales potential for DFUs.
- **NexoBrid Growth Momentum**: 2025 revenue guidance of $24M reflects 19% YoY growth, driven by European and U.S. expansion.
- **Manufacturing Readiness**: GMP facility on track for 2026 approvals, with U.S. government-backed backup capacity for military use.
- **Strategic Partnerships**: Collaborations with wound care leaders reduce trial variability and enhance commercial readiness.
- **Financial Strength**: $44M cash runway supports clinical and commercial initiatives, despite 2024 net loss of $30.2M.

**【CEO Summary Section】**
- **EscharEx Clinical Progress**: Phase 3 VALUE trial for venous leg ulcers (VLUs) is enrolling 216 patients across 40 sites, with interim analysis at 65% enrollment (mid-2026). A head-to-head Phase 2 study vs. SANTYL demonstrated faster debridement (5-6 weeks vs. 6-8 weeks) and higher complete debridement rates. Peak sales potential estimated at $725 million for diabetic foot ulcers (DFUs) and DFU Phase 2/3 trial set for 2026 with Kerecis collaboration.
- **NexoBrid Commercial Growth**: 2024 revenue of $20.2 million (+8% YoY), driven by 42% Q4 U.S. hospital orders. 2025 revenue guidance of $24 million reflects expanded European and Japanese adoption. New pediatric FDA approval and expanded access protocol confirm safety in 239 U.S. burn patients.
- **Manufacturing Expansion**: State-of-the-art GMP facility nearing completion, targeting 2026 FDA/EMA approvals. U.S. government-funded backup facility in development for military use.
- **Strategic Partnerships**: Collaborations with Solventum, Mölnlycke, MIMEDX, and Kerecis provide advanced wound care products and training, minimizing trial variability.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Revenue $5.8 million (+10% YoY), gross margin 15.5%. R&D expenses $3 million (+67% YoY) due to EscharEx trials. Net loss $3.9 million (-130% YoY) driven by warrant revaluation. Full-year 2024 cash balance $43.6 million after $25M PIPE and $1.2M EU grant.
- **2025 Outlook**: R&D spend to rise with EscharEx Phase 3 enrollment of ~100 patients at $100K/patient. Operating expenses expected to increase with commercial expansion and manufacturing ramp-up.

**【Q&A Key Takeaways】**
- **EscharEx Enrollment**: Sites targeting 0.5 patients/month, with no competing trials offering similar financial incentives. Interim analysis in mid-2026 will assess 90% success probability.
- **Medicare Policy Impact**: New LCD requiring debridement before CTP use aligns with EscharEx's clinical profile, positioning it as preferred enzymatic therapy.
- **Manufacturing Risk**: FDA/EMA inspections tied to stability data (6 months for U.S., 3 months for EU), delaying full commercial launch until 2026.
- **DFU Trial Design**: FDA/EMA protocol submission planned for H2 2025, with Phase 2/3 adaptive design based on existing DFU data.
- **Financial Flexibility**: $44M cash runway supports clinical trials, manufacturing, and partnerships without dilutive financing needs.

Actual											-0.63	-0.77	-0.49	-0.42	-0.7	-0.84	-0.84	-1.05	-0.84	-0.91	-0.91	-1.18	-0.44	0.1	-0.24	-0.19	-1.05	-0.68	-0.98	-0.36	-0.07	-1.23	-0.24	-0.56
Forecast											-0.9975	-0.84	-0.672	-0.7893	-0.7817	-0.7817	-0.9001	-1.0477	-0.756	-0.6767	-0.7	-0.3125	-0.305	-0.41	-0.4425	-0.2625	-0.4067	-0.42	-0.4767	-0.576	-0.6617	-0.5725	-0.8117	-0.6499
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+36.84%	+8.33%	+27.08%	+46.79%	+10.45%	-7.46%	+6.68%	-0.22%	-11.11%	-34.48%	-30.00%	-277.60%	-44.26%	+124.39%	+45.76%	+27.62%	-158.18%	-61.90%	-105.58%	+37.50%	+89.42%	-114.85%	+70.43%	+13.83%

MDWD

MDWD fundamentals

MDWD Q4 2025 Earnings

Earnings Call

You can ask Aime

MDWD

MDWD fundamentals

MDWD Q4 2025 Earnings

Earnings Call

MDWD Earnings Call Summary for Q4/20258:30 AM on Mar 5, 2026

MDWD Earnings Call Summary for Q3/20258:30 AM on Nov 20, 2025

MDWD Earnings Call Summary for Q2/20258:30 AM on Aug 14, 2025

MDWD Earnings Call Summary for Q1/20258:30 AM on May 21, 2025

MDWD Earnings Call Summary for Q4/20248:30 AM on Mar 19, 2025

You can ask Aime